Human gene therapy approaches for the treatment of Parkinson's disease: An overview of current and completed clinical trials

Document Type

Article

Abstract

Gene therapy has been employed in the human brain for a number of disorders in clinical trials and may serve as an avenue for the treatment of Parkinson's disease (PD). Several gene therapy treatment strategies have been developed and evaluated in patients with PD. Three main strategies have been used-enhancement of dopamine synthesis, expression of trophic factors, and neuromodulation. Typically, genes are delivered via viral vectors and expressed within neurons in PD-relevant areas of the brain such as the striatum. These methods of gene delivery have the potential for long-term expression and may only need to be delivered once. Notably, current gene therapy strategies do not address the non-motor symptoms of PD and do not curtail α-synuclein aggregation/spread. Furthermore, many of the completed trials were open-label trials and are subject to placebo effects and bias. Clinical trials have, however, demonstrated safety and studies are ongoing. Here, we review the current landscape of the development of gene therapy for PD and discuss the future of this novel treatment strategy.

Medical Subject Headings

Clinical Trials as Topic; Genetic Therapy (methods); Humans; Parkinson Disease (therapy)

Publication Date

9-1-2019

Publication Title

Parkinsonism & related disorders

E-ISSN

1873-5126

Volume

66

First Page

16

Last Page

24

PubMed ID

31324556

Digital Object Identifier (DOI)

10.1016/j.parkreldis.2019.07.018

Share

COinS